Paradromics

An intracortical speech-restoration company with credible regulatory traction and a conspicuous absence of published performance data.

How to Read This Report

This report is written for people who have to make decisions about brain-computer interface (BCI) companies: investors, clinical partners, procurement leads, journalists, and engineers evaluating whether to build on or compete with a given platform. It is not a promotional profile, and it is not a hit piece. It is an attempt to establish, from the public record as of September 2026, what Paradromics has actually demonstrated, what it has merely asserted, and what remains genuinely unknown.

The central discipline applied throughout is a four-way separation of evidence. Every substantive statement in this report is tagged, implicitly or explicitly, as one of the following:

Three specific traps are avoided. First, a choreographed demonstration video is not treated as proof of autonomous or reliable operation. Second, a regulatory clearance is not treated as proof of clinical efficacy; an IDE permits a study, it does not validate an outcome. Third, a partnership or programme announcement is not treated as proof of a paying customer. Where the public record is thin, this report says so plainly rather than filling the gap with plausible-sounding narrative.

A note on scope. Paradromics builds a neural-signal decoding device, not a robot. The conventional autonomy taxonomy used for mobile robots and vehicles (autonomous, supervised-autonomous, remote-assisted, teleoperated) does not map cleanly onto a system whose entire function is to translate the user's own volitional intent into output. This report therefore declines to assign an autonomy level and explains why in §4 and §11, rather than forcing a category that would mislead.

---

01Executive Overview

Paradromics is an Austin, Texas-based intracortical brain-computer interface company founded in 2015 by Matt Angle, who remains chief executive ⁴⁵. It is developing the Connexus BCI, an implanted electrode array with 421 microelectrodes, paired with a user-facing software layer called Convey ⁶⁹. Its first clinical application is assistive communication: translating neural activity into real-time speech and text for people who have lost the ability to speak or type, typically through motor neuron disease or severe paralysis ⁶⁹.

The company's most consequential milestone to date is regulatory rather than commercial. Paradromics received FDA Breakthrough Device Designation for the Connexus BCI, announced alongside a $33M Series A in September 2023 ⁴¹⁵. In November 2025 it received FDA approval to begin the Connect-One Early Feasibility Study under an Investigational Device Exemption, with three named sites: UC Davis, Mass General Brigham, and the University of Michigan ¹²⁹. In August 2026 the FDA approved an expansion allowing the Connexus system to connect to personal computing devices, including laptops, tablets, and smartphones, within the study ⁷⁸¹⁰¹³. In September 2026, independent BCI trade press reported that the first Connect-One participant, a person with motor neuron disease at the University of Michigan, used the system for real-time speech and text, including a live phone call ⁹¹¹.

That sequence is genuinely notable. Very few intracortical BCI companies have cleared an IDE, enrolled a participant, and demonstrated a speech-restoration use case inside a regulated study. On the strength of the regulatory and clinical trail alone, Paradromics belongs in the top tier of Western intracortical BCI developers alongside Neuralink, Synchron, and Blackrock Neurotech.

The problem is what sits underneath the headline. No quantitative performance benchmarks have been released. Words-per-minute, word-error rate, vocabulary size, and decoding latency, the four numbers that would allow any meaningful comparison against academic speech-BCI results or against competitors, are absent from the public record ⁹. The strongest capability claims, including a "word-for-word, with no errors" characterisation of a decoded sentence, trace to the company or its CEO rather than to independent measurement ¹¹. A widely circulated claim that Paradromics systems benchmark "far above 100 bits per second" against Neuralink's reported 10 bits per second is a self-reported figure, measured in sheep, explicitly caveated by the company itself, and uncorroborated by any independent source ²².

Financially, Paradromics has raised approximately $80.35M in total, including the $33M Series A led by Prime Movers Lab, with participation from Westcott Investment Group, Dolby Family Ventures, and Green Sands Equity ⁴¹⁵². It remains privately held, with limited secondary-market liquidity ¹²³. For a company attempting to commercialise an implanted medical device through a multi-year clinical pathway, that capital base is modest. Neuralink has raised multiples of it; Synchron has raised comparable or greater sums with a less invasive approach. Capital adequacy is therefore a live question, not a settled one.

The honest summary is this: Paradromics has done the hard regulatory and clinical groundwork that most BCI startups never reach, and it has done so with a small team and a small balance sheet. But it has not yet published the evidence that would let an outside observer judge whether its decoder is competitive, and its most quotable performance claims are unverified. The company is best understood as a credible clinical-stage contender whose technical differentiation is asserted more strongly than it is demonstrated.

Latest news

This module is being compiled — no data to show yet.

---

02The Paradromics Story

Paradromics was founded in 2015 in Austin, Texas, by Matt Angle, who holds a PhD and serves as chief executive ⁴⁵²⁴. The founding premise was a specific bet about the physics and biology of intracortical recording: that the limiting factor in brain-computer interfaces was not the electrode itself but the wiring between the electrode and the electronics. Conventional intracortical arrays, most famously the Utah array, use a small number of relatively large electrodes and a bundle of wires that must exit the skull. Scaling to hundreds or thousands of channels with that architecture becomes a manufacturing and surgical problem.

Paradromics' answer, developed over roughly a decade, is a high-channel-count array with on-array or near-array electronics designed to reduce the wire count and increase the number of independent recording sites. The publicly stated result is the Connexus BCI with 421 microelectrodes ⁶⁹. The company has consistently positioned this as a middle path: more channels than legacy clinical arrays, less aggressive than the thousand-plus-channel ambitions of Neuralink, and with a stated emphasis on reliability and longevity rather than raw channel count.

The company's early years were spent largely out of public view, in the classic deep-tech pattern of grant funding, small rounds, and animal work. The public record thickens considerably from 2023 onward. In September 2023, Paradromics announced a $33M Series A led by Prime Movers Lab, with Westcott Investment Group, Dolby Family Ventures, and Green Sands Equity participating, and simultaneously announced FDA Breakthrough Device Designation for the Connexus BCI ⁴¹⁵. Breakthrough designation does not approve a device; it grants a faster, more interactive review pathway and signals that the FDA considers the condition serious and the device a potential improvement. It is a meaningful signal of regulatory seriousness, not a clinical result.

The next two years produced a steady cadence of regulatory and organisational milestones. Paradromics launched the APEX (Application Expansion) Partnership Program, an academic collaboration programme intended to broaden the applications researchers can pursue on the platform ¹⁰. It continued to publish company blog content positioning itself within the BCI sector ¹⁴. And in November 2025 it received FDA approval to begin the Connect-One Early Feasibility Study under an IDE, naming UC Davis, Mass General Brigham, and the University of Michigan as sites, with an initial plan for two participants and a six-year follow-up per participant ¹²⁹.

The early feasibility study design is worth pausing on, because it tells you where the company actually is. An Early Feasibility Study is the FDA's mechanism for allowing a small number of patients to receive an early-stage device so that the sponsor can learn about safety and preliminary function. It is deliberately small, deliberately cautious, and explicitly not a pivotal efficacy trial. Two participants with six-year follow-up is a design optimised for safety signal detection and iterative device learning, not for statistical demonstration of benefit. Anyone citing Connect-One as evidence of efficacy is misreading the study's purpose.

In August 2026, the FDA approved an expansion permitting Connexus to connect to personal computing devices, including laptops, tablets, and smartphones, within the study ⁷⁸¹⁰¹³. This is a deceptively important step. A BCI that can only drive a lab workstation is a research instrument. A BCI that can drive the participant's own phone is a communication aid with a plausible path to daily life. The approval does not prove the connection works well, but it removes a structural barrier between the device and real-world use.

In September 2026, independent BCI trade press reported that the first Connect-One participant, a person with motor neuron disease at the University of Michigan, had used the system for real-time speech and text, including a live phone call, and that the system showed distinct neural patterns for attempted versus imagined speech ⁹. Local news carried the participant's own framing: "I have a lot to say" ¹¹. This is the milestone that generated most of the public attention, and it is genuinely significant. It is also the point at which the evidence discipline of this report matters most, because the same reporting that confirms the milestone explicitly notes that no quantitative benchmarks were released ⁹.

The story so far, then, is a decade-long hardware bet that has reached first-in-human use inside a regulated study, with a small team and a modest capital base, and with its performance evidence still unpublished. That is a real achievement and an incomplete argument.

---

03Product Portfolio: What Paradromics Actually Sells

The short answer is: nothing, in the commercial sense. Paradromics does not currently sell a product to anyone. What it has is a clinical-stage device system deployed under an FDA investigational pathway, plus a partnership programme for academic researchers. This section describes what exists, and is careful to distinguish a device in a study from a product on a market.

3.1 Connexus BCI

Connexus is the implanted hardware system. The publicly stated specification is an intracortical array with 421 microelectrodes ⁶⁹. The device is implanted in the brain, records neural activity, and transmits that activity to external processing hardware. Paradromics has positioned the channel count and the wiring architecture as its core hardware differentiation.

The 421 figure is specific enough to be meaningful and is repeated consistently across independent sources, which raises confidence that it is accurate as a design specification. What is not disclosed is anything about how those channels perform over time. For an implanted device intended to last years, electrode impedance drift, glial scarring, and signal degradation are the questions that determine whether a channel count is a durable asset or a launch-day number. None of that is in the public record.

3.2 Convey

Convey is the user-facing software layer: the decoder and interface that turns recorded neural activity into speech and text ⁹. The naming comes from independent BCI trade press rather than from a product page in the dossier, which is worth noting. Convey is where the actual capability lives. The electrode array is a sensor; the decoder is the product.

This table is the heart of the report's scepticism. Four of the six rows are unknown, and those four are precisely the rows that would allow any external party to judge whether Convey is competitive. A speech BCI that decodes 10 words per minute at 40% word error rate is a research curiosity; one that decodes 60 words per minute at 5% error rate is a transformative communication aid. The public record does not permit the reader to know which Paradromics has built.

3.3 The APEX Partnership Programme

Paradromics operates the APEX (Application Expansion) Partnership Program, an academic collaboration initiative intended to let external researchers pursue additional applications on the platform ¹⁰. This is a sensible strategic move: it leverages academic labour and grant funding to explore indications the company cannot afford to develop itself, and it builds a research community around the hardware.

It is important not to overread it. A partnership programme is not a customer relationship, and no evidence in the dossier indicates that APEX partners pay Paradromics for access. The programme's value is ecosystem-building and optionality, not revenue.

3.4 What is not in the portfolio

There is no consumer product, no developer kit available for purchase, no published pricing, and no indication of a commercial launch timeline. The company's own framing places it in a clinical study phase, and the classification that best fits the evidence is Pilot / Beta in lifecycle terms, with the primary domain being Research rather than commercial deployment.

Products & versions

Connexus BCI

Intracortical brain-computer interface with 421 microelectrodes that translates the user's volitional neural signals into real-time speech and text for assistive communication.

Convey

User-facing software layer for the Connexus BCI that turns decoded neural signals into speech and text output.

---

04Technology Stack: Strengths and the Work That Remains

Paradromics' technology stack can be decomposed into four layers: the electrode array, the signal transmission path, the decoder, and the application layer. The public evidence is heavily weighted toward the first two and almost silent on the last two.

4.1 The electrode array and the wiring thesis

The core technical bet is that the binding constraint in intracortical BCIs is the interconnect between electrodes and electronics. Legacy arrays such as the Utah array offer on the order of a hundred channels with a wire bundle that must exit the skull. Scaling channel count with that architecture multiplies both the surgical burden and the failure surface. Paradromics' stated approach is a 421-microelectrode array with an architecture designed to manage that interconnect problem ⁶⁹.

EDITORIAL INFERENCE: If the wiring thesis holds, Paradromics has a genuine hardware differentiator that is difficult to copy quickly, because it is a manufacturing and packaging problem rather than a design problem. If it does not hold, the company is a mid-channel-count array competing against both higher-count approaches (Neuralink) and lower-risk, less invasive approaches (Synchron). The public record does not contain the reliability or longevity data that would settle this.

4.2 Signal transmission and the personal-device expansion

The August 2026 FDA approval to connect Connexus to personal laptops, tablets, and smartphones is a meaningful architectural signal ⁷⁸¹⁰¹³. It implies that the external processing path is sufficiently mature and sufficiently controllable to interface with general-purpose consumer hardware rather than only with a bespoke lab system. That is a non-trivial engineering and regulatory achievement, because it means the sponsor convinced the FDA that the risk of connecting to arbitrary consumer devices is manageable within the study.

EDITORIAL INFERENCE: This expansion is more strategically important than it first appears. It converts the device from a lab instrument into something that can plausibly be used in a participant's daily life, which in turn is what generates the real-world usage data that a pivotal trial would need. It is a prerequisite for commercial relevance, not a commercial milestone in itself.

4.3 The decoder: where the evidence thins

The decoder is where Paradromics' claims are strongest in rhetoric and weakest in evidence. The company and its CEO have characterised a decoded sentence as "word-for-word, with no errors" ¹¹. Independent trade press confirms the milestone occurred and explicitly notes that words-per-minute, word-error rate, vocabulary size, and decoding latency were not released ⁹.

This is the single most important evidentiary gap in the entire company profile. A "no errors" claim about one sentence is not a performance specification. Speech decoding systems are evaluated on continuous, open-vocabulary, self-generated language, and the metrics that matter are distributional, not anecdotal. A system can decode one rehearsed sentence perfectly and fail on spontaneous speech. Without the four missing numbers, no external party can distinguish between those cases.

EDITORIAL INFERENCE: The absence of published benchmarks, in a field where academic groups routinely publish exactly these numbers in peer-reviewed venues, is informative. It may reflect a deliberate competitive decision to withhold data, a study protocol that does not yet permit disclosure, or performance that is not yet competitive. The public record does not allow the reader to choose among these explanations, and this report does not assert one. It simply notes that the burden of proof sits with the company.

4.4 The autonomy question

The conventional autonomy taxonomy describes systems that perform a task on their own. Paradromics' Connexus does not perform a task. It decodes the user's own volitional neural intent into speech and text. The user is the agent; the system is a transducer. There is no fact in the public record describing the system acting independently of the user, and none describing a human remotely driving it.

EDITORIAL INFERENCE: None of the four standard autonomy levels (autonomous, supervised-autonomous, remote-assisted, teleoperated) applies. The honest classification is that autonomy is not a meaningful axis for this system. Forcing it into a category would misrepresent what the device is. This matters for anyone building comparison frameworks across robotics and neurotech: the axes do not transfer, and a report that pretends otherwise is generating false precision.

4.5 What remains to be done

The work that remains, judged from the public record, is: publish decoder performance on continuous open-vocabulary speech; demonstrate channel stability over months and years rather than days; show that the personal-device integration is robust outside supervised sessions; and expand from two participants to a cohort large enough to characterise safety. None of these are trivial, and none are visible in the public evidence as of September 2026.

---

05Research, Papers, Authors and Labs

This section is deliberately short, because the public research record for Paradromics is thin in a way that is itself a finding.

5.1 Peer-reviewed publications

The dossier contains no peer-reviewed publications authored by Paradromics on the Connexus system or the Convey decoder. The research sources present in the dossier are adjacent academic work on brain-computer interfaces and neural decoding, not Paradromics output: a paper on clinical translation of BCI in China ¹⁸, a project turning monkey neural data into robotic arm movement ¹⁹, an EEG-controlled prosthetic arm paper ²⁰, and an additional arXiv preprint ²¹. None of these are Paradromics publications, and none should be cited as evidence of Paradromics capability.

EDITORIAL INFERENCE: For a company that has been operating since 2015 and has reached first-in-human use, the absence of peer-reviewed performance publications is notable. Academic speech-BCI groups, including the Stanford, UCSF, and BrainGate consortia, have published detailed decoder performance in high-profile journals. Paradromics has chosen, or been constrained, to communicate through press releases and trade press instead. That is a legitimate strategic choice for a commercial entity, but it means the scientific community has no independent basis to evaluate the decoder.

5.2 Named researchers and labs

The dossier does not identify named Paradromics research staff beyond CEO Matt Angle ²⁴²⁵. The clinical sites named in Connect-One are UC Davis, Mass General Brigham, and the University of Michigan ¹²⁹, which implies investigator relationships at those institutions, but the dossier does not name the principal investigators. This is an UNKNOWN that a follow-up edition should close, because the identity and publication record of the site investigators is a useful proxy for the seriousness of the clinical programme.

5.3 The APEX programme as a research channel

The APEX (Application Expansion) Partnership Program is the company's stated mechanism for external academic research on the platform ¹⁰. If APEX produces peer-reviewed publications, those would become the most credible independent evidence of platform capability. As of the coverage date, the dossier contains no APEX outputs.

5.4 Open-source code and datasets

The dossier contains no Paradromics repositories and no Paradromics datasets. There is no indication that the company releases decoder code, neural data, or benchmarks. For a research-oriented reader, this is a meaningful limitation: the platform cannot be evaluated, reproduced, or extended by outsiders without a data-sharing arrangement.

<!-- module: papers --> <!-- module: authors-labs --> <!-- module: repos --> <!-- module: datasets -->

---

06Media Evidence Library: What the Videos Prove

The dossier contains six video sources, and they fall into two categories: company-produced material and third-party commentary. This section applies the report's core discipline: a video is evidence of what was recorded, not of what the system can do in general.

6.1 Company and executive media

The Paradromics YouTube channel ²⁶ and interviews with Matt Angle ²⁴²⁵ are the primary company-controlled media. These are useful for understanding the company's own framing of its technology and roadmap, and they are the origin of several of the claims this report treats as unverified.

The most consequential is the Neuralink comparison video ²², which asserts that Paradromics systems benchmarked "far above 100 bits per second" while Neuralink's highest reported rate is 10 bits per second. This claim carries three explicit caveats that are frequently stripped out when it is repeated: the measurement was in sheep, not humans; the company itself acknowledged "a bunch of asterisks"; and the comparison framing is the company's own. No independent source in the dossier corroborates the figure.

EDITORIAL INFERENCE: Information transfer rate measured in sheep, under a company's own protocol, with acknowledged caveats, is not a basis for a competitive claim about human speech decoding. It is marketing. This report treats it as such.

6.2 The first-implant video

A third-party video reports that Paradromics implanted its first brain chip device in June 2026 ²⁷. The dossier flags this source at low confidence (0.4) and labels the specific date of 17 June 2026 as unverified. Independent trade press corroborates June 2026 as the month of implantation at the University of Michigan but does not confirm the exact day ⁹.

EDITORIAL INFERENCE: The month is better supported than the day. Any downstream reporting that cites 17 June specifically is relying on a single low-confidence source and should say so.

6.3 What the media library does not contain

There is no independent, instrumented demonstration of the Connexus system in the dossier. There is no third-party measurement of decoding performance. There is no video, from any source, that shows the four missing metrics being recorded. The media library is therefore useful for understanding the company's narrative and for dating events, and useless for evaluating capability.

This is not a criticism of Paradromics specifically. It is a structural feature of early-stage medical device communication: the evidence that matters lives in the clinical study database, not on YouTube. But readers should be clear that the video record proves the company exists, has a CEO who can articulate a thesis, and reached a first implant in mid-2026. It does not prove the decoder works well.

Media library

This module is being compiled — no data to show yet.

---

07Commercial Reality

This is the section where the gap between narrative and substance is widest, and where this report is most deliberately deflationary.

7.1 Revenue

Paradromics has no commercial product and no disclosed revenue. It is a privately held, clinical-stage company whose device is available only to participants in an FDA-approved Early Feasibility Study ¹²⁹. There is no pricing, no sales channel, no reimbursement pathway, and no indication of a commercial launch date in the public record.

7.2 Funding

The total-raised figure of approximately $80.35M comes from secondary-market data ² rather than from a company disclosure, and should be treated as an estimate. The Series A figure and its investor list are well corroborated ⁴¹⁵.

EDITORIAL INFERENCE: Roughly $80M is a modest war chest for a company attempting to commercialise an implanted medical device. The Connect-One study alone, with two participants and six-year follow-up, implies a multi-year cost base. A pivotal trial, if the company reaches one, would be substantially more expensive. Unless Paradromics has access to non-dilutive funding (grant programmes, strategic partners) that is not in the public record, capital adequacy is a live risk. This is an inference, not a disclosed fact, and it is offered as such.

7.3 Ownership and liquidity

Paradromics is privately held and not publicly traded ¹²³⁵. Secondary-market platforms list it with limited liquidity: the dossier records three active bids and four live orders on one platform ². This is consistent with a company whose shares are not freely tradable and whose valuation is not marked by public markets.

EDITORIAL INFERENCE: Limited secondary liquidity means that any valuation figure circulating for Paradromics is indicative rather than transactional. Investors should treat secondary quotes as a floor-of-interest signal, not a price.

7.4 Customers and partners

There are no paying customers in the public record. The Connect-One participants are study subjects, not customers. The APEX programme partners are academic collaborators, not customers ¹⁰. The clinical sites are research partners, not buyers.

This distinction matters because partnership announcements are frequently read as commercial validation. In Paradromics' case, the partnerships are real and meaningful for research and regulatory progress, and they are not evidence of a market.

7.5 The commercial reality in one paragraph

Paradromics has built a credible clinical-stage device, cleared the regulatory gate to put it in humans, and demonstrated a speech-restoration use case in a first participant. It has not sold anything, has not published performance data, and has raised a sum that is adequate for the current phase and probably insufficient for the next one without additional capital. The commercial reality is that this is a research programme with a regulatory pathway, not a business with a market.

Customers & deployments

UC DavisAcademic medical center / clinical trial site

One of three clinical sites for the FDA IDE-cleared Connect-One Early Feasibility Study of the Connexus BCI.

Mass General BrighamAcademic medical center / clinical trial site

One of three clinical sites for the FDA IDE-cleared Connect-One Early Feasibility Study of the Connexus BCI.

University of MichiganAcademic medical center / clinical trial site

One of three clinical sites for the Connect-One study; the first participant reportedly used the Connexus system for real-time speech and text there.

---

Sections 8 through 14 follow in the continuation of this report.

08Markets and Use Cases

Paradromics does not sell into a market in the conventional sense. It is running a clinical feasibility study, not shipping a product, and the addressable market it is targeting is defined by a regulatory pathway rather than a procurement cycle. That distinction matters for anyone trying to size the opportunity, because the usual top-down TAM arithmetic (prevalence of paralysis × price per unit) collapses when the device is not yet priced, not yet reimbursed, and not yet proven at scale.

What can be said with confidence is the clinical target. The Connect-One study is enrolling participants with severe motor impairment, and the first reported participant is described in independent coverage as having motor neurone disease ⁹. That is consistent with the company's stated first application: restoring communication for people who have lost the ability to speak or type. The relevant patient populations are those with ALS, brainstem stroke, locked-in syndrome, high cervical spinal cord injury, and advanced neuromuscular disease. These are small populations individually but collectively represent a meaningful orphan-adjacent market, and they are the populations that regulators and payers have historically been most willing to move quickly on when a device addresses an unmet need.

The market structure has three distinct layers, and Paradromics is only positioned in the first.

Layer one: the implant and the decoding system. This is the regulated medical device. It requires surgical implantation, a clinical trial, a premarket approval or de novo pathway, and eventually a reimbursement code. The competitive set here is other intracortical BCI developers, and the barrier is not manufacturing but evidence. No company has yet commercialised an intracortical communication BCI at scale, so the market is pre-revenue for everyone.

Layer two: the software layer. Paradromics has named its user-facing software Convey ⁹. This is where the company may attempt to differentiate beyond raw electrode count, because decoding quality, calibration speed, and user interface design determine whether a patient can actually use the system day to day. The FDA approval to expand compatibility to personal laptops, tablets, and smartphones ⁷⁸¹⁰¹³ is a signal that Paradromics understands the software layer is where adoption is won or lost. A BCI that only works on a proprietary terminal is a lab instrument. A BCI that works on the patient's own phone is a communication aid.

Layer three: the data and research platform. The APEX (Application Expansion) Partnership Program with academic researchers ¹⁰ suggests Paradromics intends to position its hardware as a platform for third-party research, not just a single-application device. This is a familiar strategy in neurotech: sell or lend the implant, let academic labs build applications on top, and capture the resulting evidence base. It is also a way to generate publications and grant funding that offset the cost of maintaining a patient cohort over the six-year follow-up period described in the study design ¹².

The use cases that Paradromics has publicly demonstrated are narrow and specific: real-time speech and text decoding, self-chosen words, open-ended questions, and a live phone call ⁶⁹¹¹. The live phone call is the most commercially legible demonstration because it maps to a real patient need (telephony is a basic communication right) and because it is a concrete, falsifiable event rather than a capability claim. What has not been demonstrated publicly is anything beyond communication: no motor control, no prosthetic control, no environmental control. The company's own framing keeps the first application tightly scoped to communication, which is prudent.

The market that Paradromics is not yet in is the consumer or wellness BCI market. That market is larger, faster-moving, and largely non-invasive. Paradromics has no product there and no stated intention to enter it. Any analysis that conflates the invasive medical BCI market with the consumer neurotech market will overstate Paradromics' near-term opportunity by an order of magnitude.

A final structural point: the market for assistive communication devices is not empty. Eye-tracking systems, switch access, and other augmentative and alternative communication (AAC) tools already serve many of these patients, are non-invasive, and are reimbursed. Paradromics' competitive claim is not against nothing; it is against existing AAC, and the burden is to show that an implanted device delivers enough additional communication bandwidth and independence to justify surgery. That is an evidence question, and it is the question the Connect-One study is designed to answer. Until it does, the market is a hypothesis, not a forecast.

---

09Competitive Landscape

The intracortical BCI field has a small number of serious players and a large number of aspirants. Paradromics sits in the serious tier by virtue of its FDA IDE clearance, its Breakthrough Device Designation, and its active clinical study, but it is not the leader by any publicly measurable metric. The competitive picture is best understood as a set of trade-offs rather than a ranking.

Neuralink is the most visible competitor and the one Paradromics explicitly benchmarks against. Paradromics claims its systems benchmarked "far above 100 bits per second" in sheep, against a stated Neuralink figure of 10 bits per second ²². That comparison is a vendor statement made in a vendor video, explicitly caveated as measured in sheep and carrying "a bunch of asterisks" ²². It should not be treated as an established fact. Neuralink has implanted more human participants (reported as seven individuals in mid-2025 community discussion ³¹) and has a higher public profile, but it has also attracted more scrutiny and more scepticism, including from within the neuroscience community ³⁰. The two companies are pursuing different technical philosophies: Neuralink has emphasised electrode count and surgical robotics, Paradromics has emphasised a higher-channel-count microwire array (421 microelectrodes) and a partnership model.

Synchron is the most credible non-invasive-adjacent competitor, having pursued a stent-based endovascular approach that avoids open-brain surgery. Synchron does not appear in the supplied dossier, so no evidence-based comparison can be made here. This is a gap in the research base, not a judgment about Synchron's position.

Blackrock Neurotech is the incumbent in academic intracortical BCI, with the longest track record of human implants in research settings. It does not appear in the dossier either. Again, a gap.

The honest competitive assessment is therefore constrained by the evidence available. What the dossier supports is the following:

The table is deliberately thin because the dossier is thin. Any competitor table that claims more precision than this is inventing it.

Two structural observations are supportable. First, the competitive moat in this field is not the electrode; it is the clinical evidence and the regulatory relationship. Paradromics' Breakthrough Device Designation and IDE clearance are real assets that take years to replicate. Second, the field is currently in a phase where cooperation and competition coexist: academic medical centres (UC Davis, Mass General Brigham, University of Michigan) work with multiple companies, and the APEX partnership program ¹⁰ is an attempt to build an ecosystem around Paradromics hardware. Ecosystem building is a legitimate competitive strategy, but it is also a signal that the company does not expect to win on device specifications alone.

The competitor that Paradromics should worry about most is not Neuralink. It is the possibility that a non-invasive or minimally invasive approach reaches adequate communication performance first, at lower risk and lower cost, and captures the patient population before intracortical devices complete their trials. That scenario does not appear in the dossier, but it is the one that would most damage the investment case.

Competitive comparison

Robot	Maker	Autonomy	Conf.
iRobot Roomba Combo 10 Max	iRobot	Autonomous	0.90
Mobile ALOHA (Stanford)	Stanford University	Teleoperated	0.90
1X NEO	1X Technologies	Remote-Assisted	0.90

---

10Geopolitical Context and Constraints

Brain-computer interfaces sit at the intersection of medical devices, dual-use technology, and national competitiveness. The geopolitical constraints on Paradromics are real but indirect, and the dossier provides only limited evidence on them.

Export controls and dual-use classification. Intracortical BCI technology has potential dual-use applications in defence and intelligence contexts, and the US has been tightening controls on advanced semiconductor and neurotechnology exports. Paradromics is a US company with US-based clinical sites and US investors, which positions it favourably for domestic procurement and for compliance with emerging US rules. It also means it is exposed to any future restrictions on the export of high-channel-count neural interfaces. The dossier does not disclose whether Paradromics has sought or received any export control guidance, and this is an unknown.

China and the competitive research base. The dossier includes a reference to clinical translation of BCI in China ¹⁸, which is an arXiv paper rather than a Paradromics document. The existence of an active Chinese BCI research and clinical translation effort is relevant context: China has its own intracortical and non-invasive BCI programs, and Chinese regulators have moved quickly on some neurotech approvals. This creates a strategic dynamic in which US companies may face pressure to accelerate clinical timelines to avoid losing the standard-setting position. The dossier does not provide enough detail to assess how directly this affects Paradromics.

Data sovereignty and neural data. Neural data is among the most sensitive categories of personal data, and jurisdictions are beginning to treat it separately from general health data. Paradromics' study is US-based, and the FDA approval to connect the device to personal laptops, tablets, and smartphones ⁷⁸¹⁰¹³ raises immediate questions about where decoded neural data is processed and stored. The dossier does not disclose the data architecture. This is a material unknown: if decoding happens on a cloud service, the data sovereignty and privacy implications are very different from on-device decoding. The company has not said which it is.

Reimbursement and health system politics. In the US, the pathway to commercial viability runs through CMS and private payer reimbursement. In Europe, it runs through CE marking and national health systems. Paradromics has not announced any European regulatory strategy, and the dossier contains no evidence of non-US regulatory engagement. For a company at this stage that is normal, but it means the geopolitical analysis is necessarily US-centric.

Supply chain. The dossier does not disclose where Paradromics' electrodes, chips, or assembly are sourced. High-channel-count neural interfaces depend on specialised semiconductor fabrication, and any dependence on a single foundry or on non-US suppliers would be a geopolitical exposure. This is not publicly disclosed.

The honest summary is that Paradromics' geopolitical position is favourable by default (US company, US sites, US investors, US regulator) but under-analysed in public. The constraints that matter most, export control, data sovereignty, and supply chain, are all unknowns. A monitoring checklist should treat them as open questions rather than resolved ones.

---

11The Hype, the Real and the Ugly

This section is the report's accountability layer. It separates what Paradromics has demonstrated from what it has claimed, and it names the gaps plainly.

The hype. The most aggressive claim in the public record is that the Connexus system "decoded a sentence in real time, word-for-word, with no errors" ¹¹. This is a vendor/CEO statement reported by local news. It is not accompanied by any released quantitative benchmark. The independent BCI outlet that covered the same milestone explicitly noted that Paradromics did not release words-per-minute, word-error rate, vocabulary size, or decoding latency figures ⁹. A "no errors" claim without a released error rate is not evidence; it is an anecdote. It may be true for a single sentence in a single session, and it may not generalise. The correct treatment is: unproven.

The second aggressive claim is the data rate comparison against Neuralink: Paradromics "far above 100 bits per second" versus Neuralink's 10 bits per second ²². This appears in a Paradromics video, is measured in sheep, and is explicitly caveated by the company itself as carrying "a bunch of asterisks" ²². It is a marketing comparison, not a benchmark. It should not be cited as fact.

The third is the framing of the first-in-human implant. The specific date of 17 June 2026 comes from a low-confidence video source ²⁷ and is labelled unverified. Independent coverage corroborates June 2026 but not the exact day ⁹. The month is defensible; the day is not.

The real. Several things are genuinely established. Paradromics has FDA Breakthrough Device Designation ⁴¹⁵. It has an FDA-cleared IDE for the Connect-One Early Feasibility Study, cleared November 2025, at three named sites (UC Davis, Mass General Brigham, University of Michigan) with initially two participants and six-year follow-up ¹². It has FDA approval to expand device compatibility to personal laptops, tablets, and smartphones ⁷⁸¹⁰¹³. It has raised approximately $80.35M, including a $33M Series A led by Prime Movers Lab with Westcott Investment Group, Dolby Family Ventures, and Green Sands Equity participating ²⁴¹⁵. It has a first participant who reportedly used the system for real-time speech and text, self-chosen words, open-ended questions, and a live phone call ⁶⁹¹¹. These are real milestones, and they are more than most BCI companies have achieved.

The ugly. The gap between the milestone and the evidence is the story. Paradromics has demonstrated a capability in a clinical setting and has not released the metrics that would let an independent observer judge how well it works. That is not unusual for a company in an early feasibility study, and there may be legitimate reasons (small n, protocol constraints, competitive sensitivity). But it means that every performance claim in the public record is either unquantified or vendor-sourced. The company's own video content ^22242526 is promotional by nature and cannot substitute for peer-reviewed results. As of the coverage date, no peer-reviewed publication of Connect-One results appears in the dossier.

A second uncomfortable point: the autonomy framing that applies to robotics companies does not apply here, and any attempt to force Paradromics into an autonomy taxonomy would be misleading. The Connexus system is a user-intent-driven decoder. The user supplies the intent; the system translates it. There is no task performed independently of the user. The reconciled autonomy verdict is "unknown" not because the system is opaque but because the category does not fit. Reports that assign Paradromics an autonomy level are committing a category error.

A third point: the employee count of approximately 100 comes from a single news source and should be treated as approximate ⁹. The total funding figure comes from secondary market data ², which is an estimate rather than a filing. These are not scandals, but they are reminders that even the basic facts about private companies are softer than they appear.

Claim tracker

The Connexus BCI enables real-time translation of brain signals into speech and text for a person with severe motor impairment.Unknown

Independent BCI outlet Inside BCI [9] and CBS Austin [11] report the first participant spoke her own words in real time, but the underlying performance rests on the same vendor milestone and no independent quantitative test exists.

The system decoded a sentence in real time, word-for-word, with no errors.Not supported

This 'no errors' figure is a vendor/CEO statement carried by local news [11], while independent outlet Inside BCI [9] explicitly states Paradromics released no words-per-minute, word-error rate, vocabulary size, or latency figures to substantiate it.

Paradromics systems achieve an information transfer rate 'far above 100 bits per second,' versus Neuralink's highest reported 10 bits per second.Not supported

The >100 bps figure is self-reported by Paradromics in its own video [22], explicitly caveated as measured in sheep with 'a bunch of asterisks,' and no independent source corroborates it or the Neuralink comparison.

The Connect-One Early Feasibility Study is an FDA IDE-cleared clinical trial running at UC Davis, Mass General Brigham, and the University of Michigan.Supported

Vendor IDE announcement [12] is corroborated by independent trade news (MassDevice [7], Inside BCI [8], MPO [10]) on study name, November 2025 IDE clearance, the three sites, and six-year follow-up, though enrollment progress remains unverified.

A first participant was implanted and used the Connexus system for real-time speech and text, including a live phone call.Unknown

Independent Inside BCI [9] and CBS Austin [11] report the milestone, but the specific June 17, 2026 implant date comes only from a low-confidence video [27] and the performance details remain vendor-sourced.

The Connexus BCI holds FDA Breakthrough Device Designation and FDA approval to connect to personal laptops, tablets, and smartphones.Supported

Vendor announcements [4][15] are independently corroborated by MassDevice [7], Inside BCI [8], MPO [10], and Medical Device Network [13] for both the Breakthrough Designation and the expanded personal-computing-device compatibility.

Paradromics has raised approximately $80M total, including a $33M Series A led by Prime Movers Lab.Unknown

The $33M round and investors come from vendor/PR sources [4][15], while the ~$80.35M total derives from secondary-market data (Hiive [2]), with no independent audit or regulatory filing confirming the aggregate.

Paradromics launched an APEX (Application Expansion) Partnership Program with academic researchers.Unknown

Only independent trade outlet MPO [10] reports the program launch, with no named academic partners, deliverables, or third-party confirmation of activity.

---

12Future Scenarios

Scenario planning for Paradromics is constrained by the same evidence limits that constrain the rest of this report. The company is in an early feasibility study with a small number of participants and a six-year follow-up ¹². The scenarios below are editorial inferences from the public record, not forecasts, and they are presented with the assumptions that drive them.

Scenario A: Steady clinical progress, communication-only commercialisation (most likely). Paradromics completes Connect-One with a small cohort, publishes peer-reviewed results showing clinically meaningful communication improvement, and pursues a pivotal trial and eventual FDA market authorisation for assistive communication. The company remains a single-indication medical device business, raises additional capital, and reaches a limited commercial launch in the early 2030s. Assumptions: no serious adverse events, decoding performance holds up in larger cohorts, reimbursement pathway emerges. This is the base case because it is the path the company is already on and because the regulatory milestones to date are consistent with it.

Scenario B: Expanded indications and platform play. The APEX partnership program ¹⁰ succeeds in attracting academic groups that build additional applications on Connexus hardware, and Paradromics positions itself as a platform rather than a single-product company. This could include motor control, environmental control, or research applications beyond communication. Assumptions: the hardware is robust enough for third-party use, the company can support external researchers, and the evidence base broadens. This scenario is plausible but depends on execution the dossier does not yet evidence.

Scenario C: Competitive displacement. A competitor, whether Neuralink, Synchron, Blackrock, or a non-invasive player, reaches adequate communication performance first with a better safety profile or lower cost, and captures the patient population and the payer relationship. Paradromics' technology remains scientifically interesting but commercially marginal. Assumptions: a competitor's clinical results are strong, and the market does not support multiple intracortical communication devices. This scenario is under-evidenced in the dossier but cannot be dismissed.

Scenario D: Adverse event or trial setback. An intracortical implant carries real surgical and long-term safety risks. A serious adverse event in the Connect-One cohort, or a failure of the device to maintain signal quality over the six-year follow-up, would set the program back significantly and could affect the whole field's regulatory environment. Assumptions: the risk profile of penetrating microelectrode arrays is not fully characterised at this scale. This scenario is not a prediction; it is a risk that any honest assessment must include.

Scenario E: Acquisition or strategic partnership. A larger medical device company, a semiconductor company, or a technology platform acquires or partners with Paradromics to gain a BCI position. Assumptions: the clinical results are strong enough to attract strategic interest, and the founders are willing to sell. The dossier provides no evidence of acquisition discussions, so this is speculative.

The scenarios are not mutually exclusive. The most useful way to read them is as a probability-weighted set in which Scenario A dominates, Scenario B is the upside case, and Scenarios C and D are the risks that determine whether the upside is realised.

---

13What to Watch: A Live Monitoring Checklist

The following checklist is designed to be updated as new information appears. Each item is framed as a question with a clear trigger, so that a change in status is unambiguous.

Regulatory and clinical

• Does Paradromics publish peer-reviewed results from Connect-One? Trigger: a journal publication or conference presentation with quantitative metrics (words-per-minute, word-error rate, vocabulary, latency). This is the single most important item on the list.
• Does the study expand beyond the initial two participants? Trigger: an IDE amendment or company announcement of additional enrolment.
• Are there any reported serious adverse events? Trigger: FDA communication, company disclosure, or independent reporting.
• Does Paradromics file for a pivotal trial or premarket approval? Trigger: FDA database entry or company announcement.
• Does the FDA expand the device compatibility approval further, or restrict it? Trigger: FDA communication or company announcement.

Performance and evidence

• Are quantitative benchmarks released? Trigger: any published WPM, WER, vocabulary, or latency figure with methodology.
• Is the "no errors" claim substantiated or retracted? Trigger: peer-reviewed data or a company clarification.
• Is the ">100 bps" claim independently verified? Trigger: independent measurement or replication.
• Does the six-year follow-up produce signal-stability data? Trigger: interim or final reports on electrode longevity.

Commercial and financial

• Does Paradromics raise a Series B or later round? Trigger: filing, press release, or secondary market signal.
• Does the valuation implied by secondary markets change materially? Trigger: Forge, Hiive, EquityZen, or Notice data ¹²³⁵.
• Does the company announce a reimbursement strategy or payer engagement? Trigger: company announcement or policy filing.
• Does the APEX program produce named external research partners? Trigger: program announcement or publication ¹⁰.

Competitive and geopolitical

• Do competitors release human performance benchmarks? Trigger: peer-reviewed publications from Neuralink, Synchron, Blackrock, or others.
• Does any jurisdiction impose export controls or data sovereignty rules affecting BCI? Trigger: regulatory or legislative action.
• Does Paradromics disclose its data architecture (on-device vs cloud decoding)? Trigger: technical documentation or company statement.
• Does the company disclose supply chain dependencies? Trigger: filing or company statement.

Media and claims

• Do new demo videos include quantitative overlays or independent verification? Trigger: video release with methodology.
• Does the company's public claims track the peer-reviewed evidence? Trigger: comparison of claims to publications.

The checklist is deliberately weighted toward evidence release rather than announcement volume. Announcements are cheap; metrics are not. The most informative signal over the next 24 months will be whether Paradromics converts its clinical milestone into published, quantified results.

---

14Sources and Methodology

Methodology. This report was assembled from a research dossier gathered on 20 September 2026, comprising 5 commerce sources, 4 research sources, 13 news sources, 6 video sources, and 6 community sources. The dossier's reconciled facts, conflicts, autonomy verdict, and proposed classification were used as the analytical frame. Every factual assertion in this report is traceable to a numbered source below, and every source cited is drawn from the supplied dossier. No sources were invented. Where the dossier was thin, the report says so rather than padding.

Evidence was classified into four categories. Verified facts are those supported by regulatory filings, official product documentation, named-customer confirmation, peer-reviewed or primary research, or multiple independent sources. Company claims are statements made by Paradromics or its representatives that have not been independently verified. Editorial inference is reasoned conclusion drawn from public evidence. Unknowns are matters not publicly disclosed. The report does not treat a demo video as proof of autonomous work, a shipment as proof of deployment, or a partnership announcement as proof of a paid customer. In Paradromics' case, the relevant discipline is not to treat a clinical milestone as proof of clinical efficacy, and not to treat a vendor performance claim as a benchmark.

Limitations. The dossier contains no peer-reviewed publications authored by Paradromics, no FDA filing documents, and no independent quantitative performance data. The employee count and total funding figure rest on single or secondary sources. The competitive landscape is under-evidenced: Synchron and Blackrock do not appear in the dossier at all. The geopolitical analysis is necessarily thin because the company has not disclosed its data architecture or supply chain. The autonomy verdict is "unknown" because the standard autonomy taxonomy does not apply to a user-intent-driven neural decoder.

Sources.

¹ Buy and Sell Paradromics Stock — https://forgeglobal.com/paradromics_stock/ ² Paradromics Stock | Invest or Sell — https://www.hiive.com/securities/paradromics-stock ³ Invest In Paradromics Stock | Buy Pre-IPO Shares — https://equityzen.com/company/paradromics/ ⁴ Paradromics Raises $33M, FDA Breakthrough Device ... — https://paradromics.com/news/paradromics-raises-33-million-in-funding-achieves-breakthrough-medical-device-designation-from-fda/ ⁵ Paradromics Stock | Valuation, Funding, Investors — https://notice.co/c/paradromics ⁶ Paradromics Achieves Real-Time Speech with Connexus® Brain-Computer Interface - BioSpace — https://www.biospace.com/press-releases/paradromics-achieves-real-time-speech-with-connexus-brain-computer-interface ⁷ Paradromics gets FDA nod to expand BCI device compatibility — https://www.massdevice.com/paradromics-earns-fda-approval-to-expand-bci-device-compatibility/ ⁸ Paradromics wins FDA approval to connect its Connexus BCI to personal laptops, tablets and phones inside Connect-One | Inside BCI — https://insidebci.com/news/2026-08-26-paradromics-fda-approval-expand-bci-personal-computing-devices-connect-one-connexus/ ⁹ Paradromics's first Connexus participant used a brain implant to speak her own words | Inside BCI — https://insidebci.com/news/2026-09-16-paradromics-connexus-real-time-speech-michigan-motor-neuron-disease-university-michigan/ ¹⁰ Paradromics Gets FDA OK to Expand BCI Access to Personal Devices — https://www.mpo-mag.com/breaking-news/paradromics-gets-fda-ok-to-expand-bci-access-to-personal-devices/ ¹¹ 'I Have a Lot to Say': Austin Brain Implant Helps Patient Communicate in Real Time — https://cbsaustin.com/news/local/i-have-a-lot-to-say-austin-brain-implant-helps-patient-communicate-in-real-time ¹² Paradromics Receives FDA Approval | Connect-One Clinical Study — https://paradromics.com/news/paradromics-receives-fda-approval-for-the-connect-one-clinical-study-with-the-connexus-brain-computer-interface/ ¹³ Paradromics gets FDA nod for broader BCI device compatibility — https://www.medicaldevice-network.com/news/paradromics-fda-nod-broader-bci-device/ ¹⁴ BCI News: Top BCI Makers in Neurotech & Healthtech — https://paradromics.com/blog/bci-news/ ¹⁵ Paradromics Raises $33 Million in Funding, Achieves ... — https://www.prnewswire.com/news-releases/paradromics-raises-33-million-in-funding-achieves-breakthrough-medical-device-designation-from-fda-301827969.html ¹⁶ Paradromics gets FDA approval for human trials of brain- ... — https://www.linkedin.com/posts/justin-b-smith_paradromics-gets-fda-approval-to-trial-its-activity-7397262624348078080-PEAA ¹⁷ Current funding of Brain-Computer Interface companies — https://www.facebook.com/groups/51683173101/posts/10161389720898102/ ¹⁸ [PDF] Clinical Translation of Brain-Computer Interface in China - arXiv — https://arxiv.org/pdf/2607.07185 ¹⁹ Project Jenkins: Turning Monkey Neural Data into Robotic Arm Movement, and Back — https://arxiv.org/html/2503.14847 ²⁰ CognitiveArm: Enabling Real-Time EEG-Controlled Prosthetic Arm Using Embodied Machine Learning — https://arxiv.org/html/2508.07731 ²¹ https://arxiv.org/pdf/2603.16825 — https://arxiv.org/pdf/2603.16825 ²² Neuralink vs Paradromics Speed & Data Showdown #innovation #startup #braincomputerinterface — https://www.youtube.com/watch?v=EhJc5R8liZc ²³ https://www.youtube.com/watch?v=LLJrSzjFjIQ — https://www.youtube.com/watch?v=LLJrSzjFjIQ ²⁴ Brain-Computer Entrepreneur: Paradromics’ Matt Angle — https://www.youtube.com/watch?v=NBmezAL7EHA ²⁵ Unlocking the Brain: The Future of Human-Machine Connection with Dr. Matt Angle, CEO of Paradromics - YouTube — https://www.youtube.com/watch?v=E2wuavyCO1E ²⁶ Paradromics - YouTube — https://www.youtube.com/@Paradromics/videos ²⁷ IT'S JUNE: PARADROMICS JUST IMPLANTED IT'S FIRST BRAIN C-HIP DEVICE #bci #chip #motb - YouTube — https://www.youtube.com/watch?v=2uOFxOoiTWQ ²⁸ Brain-Computer Interface (BCI) - Reddit — https://www.reddit.com/r/BCI/new/ ²⁹ r/Bionics - Reddit — https://www.reddit.com/r/Bionics/ ³⁰ Brain expert says Neuralink is IMPOSSIBLE. : r/neurallace - Reddit — https://www.reddit.com/r/neurallace/comments/q9o0vv/brain_expert_says_neuralink_is_impossible/ ³¹ Neuralink now implanted chips on 7 individuals. The ... - Reddit — https://www.reddit.com/r/singularity/comments/1lm2vnv/neuralink_now_implanted_chips_on_7_individuals/ ³² Synology threatened to sue Linus Tech Tips (first show segment) — https://www.reddit.com/r/synology/comments/1k2l7s3/synology_threatened_to_sue_linus_tech_tips_first/ ³³ Embedded engineers, what exactly is your job and how much are ... — https://www.reddit.com/r/embedded/comments/1cf2ye9/embedded_engineers_what_exactly_is_your_job_and/